Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension

The Lancet

Volumn 375, Issue 9718, 2010, Pages 895-905

  Rothwell, Peter M ^a   Howard, Sally C ^a   Dolan, Eamon ^b   O'Brien, Eoin ^c   Dobson, Joanna E ^d   Dahlöf, Bjorn ^e   Sever, Peter S ^d   Poulter, Neil R ^d  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b Royal College of Surgeons in Ireland   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; DIPYRIDAMOLE; PERINDOPRIL;

ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; BLOOD PRESSURE VARIABILITY; CEREBROVASCULAR ACCIDENT; DIAGNOSTIC ACCURACY; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYPERTENSION; MEAN ARTERIAL PRESSURE; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; RISK ASSESSMENT; RISK FACTOR; STROKE; SYSTOLIC BLOOD PRESSURE; TRANSIENT ISCHEMIC ATTACK; VALIDATION STUDY;

EID: 77749251836     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60308-X     Document Type: Article

References (52)

1. Warlow C., Sudlow C., Dennis M., Wardlaw J., and Sandercock P. Stroke. Lancet 362 (2003) 1211-1224
2. Lawes C.M., Vander Hoorn S., Rodgers A., and for the International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 371 (2008) 1513-1518
3. MacMahon S., Peto R., Cutler J., et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335 (1990) 765-774
4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360 (2002) 1903-1913
5. Williams B., Lindholm L.H., and Sever P. Systolic pressure is all that matters. Lancet 371 (2008) 2219-2221
6. Leenen F.H. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome. Can J Cardiol 20 suppl B (2004) 77B-82B
7. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull F., Neal B., Ninomiya T., et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 336 (2008) 1121-1123
8. OBrien E., Asmar R., Beilin L., et al., on behalf of the European Society of Hypertension Working Group on BP Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self BP measurement. J Hypertens 23 (2005) 697-701
9. Chobanian A.V., Bakris G.L., Black H.R., et al., and the National High BP Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection and Evaluation, and Treatment of High BP. Hypertension 42 (2005) 1206-1252
10. Mancia G., De Backer G., Dominiczak A., et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25 (2007) 1105-1187
11. Parati G., Stergiou G.S., Asmar R., et al. ESH Working Group on BP Monitoring. European Society of Hypertension guidelines for BP monitoring at home: a summary report of the Second International Consensus Conference on Home BP Monitoring. J Hypertens 26 (2008) 1505-1526
12. Rothwell P.M. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet 375 (2010) 938-948
13. Rothwell P.M., Coull A.J., Silver L.E., et al., for the Oxford Vascular Study. Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet 366 (2005) 1773-1783
14. Armitage P., Fox W., Rose G.A., and Tinker C.M. The variability of measurements of causal blood pressure. II Survey experience. Clin Sci 30 (1966) 337-344
15. Klungel O.H., de Boer A., Paes A.H., Nagelkerke N.J., Seidell J.C., and Bakker A. Estimating the prevalence of hypertension corrected for the effect of within-person variability in blood pressure. J Clin Epidemiol 53 (2000) 1158-1163
16. Turner M.J., and van Schalkwyk J.M. Blood pressure variability causes spurious identification of hypertension in clinical studies: a computer simulation study. Am J Hypertens 21 (2008) 85-91
17. Marshall T. When measurements are misleading: modelling the effects of blood pressure misclassification in the English population. BMJ 328 (2004) 933
18. Keenan K., Hayen A., Neal B.C., and Irwig L. Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 338 (2009) b1492
19. Howard S.C., and Rothwell P.M. Regression dilution of systolic and diastolic BP in patients with established cerebrovascular disease. J Clin Epidemiol 56 (2003) 1084-1091
20. Cuffe R.L., Howard S.C., Algra A., Warlow C.P., and Rothwell P.M. Medium-term variability of BP and potential underdiagnosis of hypertension in patients with previous transient ischemic attack or minor stroke. Stroke 37 (2006) 2776-2783
21. Colandrea M.A., Griedman G.D., Nichaman M.Z., et al. Systolic hypertension in the elderly: an epidemiological assessment. Circulation 41 (1970) 239
22. Marshall T. When measurements are misleading: modelling the effects of BP misclassification in the English population. BMJ 328 (2004) 933
23. Hypertension Detection and Follow-up Program Cooperative Group. Variability of BP and the results of screening in the hypertension detection and follow-up program. J Chronic Dis 31 (1978) 651
24. Whelton P.K., and Klag M.J. Epidemiology of high BP. Clin Geriatr Med 5 (1989) 639-655
25. Verdecchia P., O'Brien E., Pickering T., et al., for the European Society of Hypertension Working Group on Blood Pressure Monitoring. When can the practicing physician suspect white coat hypertension? Statement from the Working Group on Blood Pressure Monitoring of the European Society of Hypertension. Am J Hypertens 16 (2003) 87-91
26. Pickering T.G., Eguchi K., and Kario K. Masked hypertension: a review. Hypertens Res 30 (2007) 479-488
27. Howard S.C., and Rothwell P.M. Reproducibility of measures of visit-to-visit variability in blood pressure after transient ischaemic attack or minor stroke. Cerebrovasc Dis 28 (2009) 331-340
28. Cuffe R.L., and Rothwell P.M. Medium-term variability in systolic blood pressure is an independent predictor of stroke. Cerebrovasc Dis 19 suppl 2 (2005) 51 (abstr).
29. Farrell B., Godwin J., Richards S., and Warlow C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 54 (1991) 1044-1054
30. The ESPS Group. The European Stroke Prevention Study (ESPS). Principal end-points. Lancet 330 (1987) 1351-1354
31. The Dutch TIA Study Group. A comparison of two doses of aspirin (30mg vs 283mg a day) in patients after a transient ischaemic attack or minor ischaemic stroke. N Engl J Med 325 (1991) 1261-1266
32. Dahlöf B., Sever P.S., Poulter N.R., et al., for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 366 (2005) 895-906
33. Poulter N.R., Wedel H., Dahlöf B., et al., for the ASCOT investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 366 (2005) 907-913
34. Zhang Z., and Oppenheimer S.M. Electrophysiological evidence for reciprocal insulo-insular connectivity of baroreceptor-related neurons. Brain Res 863 (2000) 25-41
35. Robinson T., Ward-Close S., and Potter J. A comparison of beat-to-beat BP variability in acute and subacute stroke patients with cerebral infarction. Cerebrovas Dis 7 (1997) 214-219
36. O'Brien E., Mee F., and Atkins N. An accurate automated device for home BP measurement at last! The Omron HEM-705C. J Hypertens 12 (1994) 1317-1318
37. O'Brien E., McInnes G.T., Stanton A., et al., Anglo-Scandinavian Cardiac Outcomes Trial. Ambulatory blood pressure monitoring and 24-h blood pressure control as predictors of outcome in treated hypertensive patients. J Hum Hypertens 15 suppl 1 (2001) S47-S51
38. Dolan E., Stanton A.V., Thom S., et al., for the ASCOT Investigators. Ambulatory blood pressure monitoring predicts cardiovascular events in treated hypertensive patients-an Anglo-Scandinavian cardiac outcomes trial substudy. J Hypertens 27 (2009) 876-885
39. O'Brien E., Mee F., Atkins N., and O'Malley K. Accuracy of the SpaceLabs 90207 determined by the British Hypertension Protocol. J Hypertens 9 (1991) 573-574
40. Rothwell P.M., Howard S.C., Dolan E., et al., on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol (2010) 10.1016/S1474-4422(10)70066-1 published online March 12.
41. Webb A., Fischer U., Mehta Z., and Rothwell P.M. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet 375 (2010) 906-915
42. Kikuya M., Ohkubo T., Metoki H., et al. Day-by-day variability of blood pressure and heart rate at home as a novel predictor of prognosis: the Ohasama study. Hypertension 52 (2008) 1045-1050
43. Hata Y., Kimura Y., Muratani H., et al. Office BP variability as a predictor of brain infarction in elderly hypertensive patients. Hypertens Res 23 (2000) 553-560
44. Hata Y., Muratani H., Kimura Y., et al. Office BP variability as a predictor of acute myocardial infarction in elderly patients receiving antihypertensive therapy. J Hum Hypertens 16 (2002) 141-146
45. Tozawa M., Iseki K., Yoshi S., and Fukiyama K. BP variability as an adverse prognostic risk factor in end-stage renal disease. Nephrol Dial Transplant 14 (1999) 1976-1981
46. Havlik R.J., Foley D.J., Sayer B., Masaki K., White L., and Launer L.J. Variability in midlife systolic BP is related to late-life brain white matter lesions: the Honolulu-Asia Aging study. Stroke 33 (2002) 26-30
47. Pringle E., Phillips C., Thijs L., et al., for the Syst-Eur investigators. Systolic BP variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population. J Hypertens 21 (2003) 2251-2257
48. Jansen P.A., Schulte B.P., Meyboom R.H., and Gribnau F.W. Antihypertensive treatment as a possible cause of stroke in the elderly. Age Ageing 15 (1986) 129-138
49. PROGRESS Management Committee. Blood pressure lowering for the secondary prevention of stroke: rationale and design for PROGRESS. Perindopril Protection Against Recurrent Stroke Study. J Hypertens 14 suppl (1996) S41-S45
50. Rodgers A., MacMahon S., Gamble G., Slattery J., Sandercock P., and Warlow C. BP and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 313 (1996) 147-148
51. Toschke A.M., Wolfe C.D., Heuschmann P.U., Rudd A.G., and Gulliford M. Antihypertensive treatment after stroke and all-cause mortality-an analysis of the General Practitioner Research Database (GPRD). Cerebrovasc Dis 28 (2009) 105-111
52. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 358 (2001) 1033-1041